Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.37 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887550 | 1.00 | MEN1 (0.44) | MEN1LMNAMAPTKMT2AL3MBTL1 | |
| SCHEMBL1884907 | 0.81 | L3MBTL1 (0.44) | LMNAL3MBTL1POLBSLC22A2CES2 | |
| SCHEMBL1884905 | 0.81 | L3MBTL1 (0.44) | LMNAL3MBTL1POLBSLC22A2CES2 | |
| SCHEMBL5648866 | 0.75 | LMNA (0.60) | MEN1LMNAKMT2AL3MBTL1TDP1 | |
| SCHEMBL4749826 | 0.73 | CCKBR (0.52) | MEN1KMT2AL3MBTL1POLB | |
| SCHEMBL10487910 | 0.70 | AKR1B1 (0.53) | MEN1LMNAKMT2AL3MBTL1AKR1C2 | |
| SCHEMBL5646731 | 0.70 | SMN1; SMN2 (0.51) | LMNATDP1POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL15092388 | 0.70 | FPR2 (0.44) | LMNAL3MBTL1POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL15053941 | 0.70 | ACACB (0.47) | L3MBTL1 | |
| SCHEMBL1668405 | 0.70 | L3MBTL1 (0.54) | MEN1LMNAMAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947833-B2 | methods that are useful in the preparation of amidophenyl-sulfonylamino-quinoxaline compounds CCK2 modulators are disclosed by sulfonylation | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7563895-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-21 | — | — | US | disclosed |
| EP-1651621-B1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-06 | — | — | EP | disclosed |
| US-20080103300-A1 | PREPARATION OF QUINOXALINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| US-20080076918-A1 | QUINOXALINE COMPOUNDS | ALLISON BRETT D | 2008-03-27 | — | — | US | disclosed |
| US-7304051-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-04 | — | — | US | disclosed |
| US-7288651-B2 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-30 | — | — | US | disclosed |
| EP-1651622-B1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-07 | — | — | EP | disclosed |
| US-20050043310-A1 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| US-20050038032-A1 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103300-A1 | PREPARATION OF QUINOXALINE COMPOUNDS | CCKAR, CCKBR, GIPR | MEN1 610/4885LMNA 2703/4885MAPT 4849/4885 |
| US-20050043310-A1 | Preparation of quinoxaline compounds | CCKAR, CCKBR, GIPR | MEN1 610/4885LMNA 2703/4885MAPT 4849/4885 |
| US-20050038032-A1 | Quinoxaline compounds | CCKAR, CCKBR, GIPR | MEN1 1986/4885LMNA 4073/4885MAPT 4633/4885 |
| US-20080076918-A1 | QUINOXALINE COMPOUNDS | CCKAR, CCKBR, GIPR | MEN1 1986/4885LMNA 4073/4885MAPT 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.